Significant Decrease of Osteoporosis and Osteoporotic Fractures in Rheumatoid Arthritis Within a Period of 24 Years: Experiences of a Single Centre

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2024 Aug 20

PMID 39164051

Authors

Peter Oelzner

Paul-Heinrich Mueller

Tobias Hoffmann

Antje Schwabe

Gabriele Lehmann

Thorsten Eidner

Gunter Wolf

Alexander Pfeil

Affiliations

Soon will be listed here.

Abstract

Objectives: Rheumatoid arthritis (RA) is associated with an increased risk for osteoporosis and osteoporotic fractures. Since the treatment of RA has improved significantly in recent years, we can expect RA-associated osteoporosis to decrease with good disease control. Therefore, we conducted a retrospective study to investigate whether the frequency of osteoporosis and osteoporotic fractures has changed during 24 years in RA.

Methods: We analysed the data of 1.086 RA patients from the time of the first osteological assessment with bone mineral density (BMD) measurement and collection of osteologically important data during the years 1996 and 2019 at our clinic. According to the treatment period, the patients were divided into cohort 1 (investigation between 1996 and 2004; n=539) and cohort 2 (investigation between 2005 and 2019; n=547). The data of the two cohorts were compared, and predictors of BMD were analysed by linear regression analysis.

Results: Prevalence of osteoporosis (28.3% vs 48.4%; p<0.001) as well as osteoporotic peripheral fractures (11.5% vs 21%; p<0.001) and vertebral fractures (6.6% vs 10.9%; p=0.011) were significantly lower and treatment with biologicals (19.7% vs 5.0%; p<0.001) significantly more common and glucocorticoid use was significantly less common (p=0.005) in cohort 2. In RA patients with a disease duration of more than 2 years, BMD was significantly higher under treatment with biologicals (p<0.001) despite increased cumulative glucocorticoid dosages (p<0.001).

Conclusion: Our study showed a significant decline in osteoporosis and osteoporotic fractures in RA for 24 years. This positive effect is associated with the more frequent use of biologicals in the years between 2005 and 2019.

References

Hu Z, Zhang L, Lin Z, Zhao C, Xu S, Lin H . Prevalence and risk factors for bone loss in rheumatoid arthritis patients from South China: modeled by three methods. BMC Musculoskelet Disord. 2021; 22(1):534. PMC: 8199806. DOI: 10.1186/s12891-021-04403-5. View

Guanabens N, Olmos J, Hernandez J, Cerda D, Hidalgo Calleja C, Martinez Lopez J . Vertebral fractures are increased in rheumatoid arthritis despite recent therapeutic advances: a case-control study. Osteoporos Int. 2021; 32(7):1333-1342. DOI: 10.1007/s00198-021-05824-7. View

Coulson K, Reed G, Gilliam B, Kremer J, Pepmueller P . Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009; 15(4):155-60. DOI: 10.1097/RHU.0b013e3181a5679d. View

Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T . Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study. Rheumatol Int. 2018; 38(5):777-784. DOI: 10.1007/s00296-017-3922-z. View

Takahashi K, Setoguchi T, Tawaratsumida H, Arishima Y, Tominaga H, Ishidou Y . Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics. BMC Musculoskelet Disord. 2015; 16:269. PMC: 4589107. DOI: 10.1186/s12891-015-0732-x. View

Haugeberg G, Orstavik R, Uhlig T, Falch J, Halse J, Kvien T . Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis.... Ann Rheum Dis. 2002; 61(12):1085-9. PMC: 1753963. DOI: 10.1136/ard.61.12.1085. View

Pierini F, Brom M, Scolnik M, Scaglioni V, Rosa J, Soriano E . Osteoporotic fractures in rheumatoid arthritis patients in Argentina: a matched retrospective cohort study. Adv Rheumatol. 2021; 61(1):21. DOI: 10.1186/s42358-021-00179-3. View

Tanaka Y . Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. J Clin Med. 2021; 10(6). PMC: 8002542. DOI: 10.3390/jcm10061241. View

Orstavik R, Haugeberg G, Uhlig T, Falch J, Halse J, Hoiseth A . Vertebral deformities in 229 female patients with rheumatoid arthritis: associations with clinical variables and bone mineral density. Arthritis Rheum. 2003; 49(3):355-60. DOI: 10.1002/art.11118. View

10.

Theander L, Willim M, Nilsson J, Karlsson M, Akesson K, Jacobsson L . Changes in bone mineral density over 10 years in patients with early rheumatoid arthritis. RMD Open. 2020; 6(1). PMC: 7046965. DOI: 10.1136/rmdopen-2019-001142. View

11.

Choi S, Kwon S, Jung J, Kim H, Kim S, Kim S . Prevalence and Fracture Risk of Osteoporosis in Patients with Rheumatoid Arthritis: A Multicenter Comparative Study of the FRAX and WHO Criteria. J Clin Med. 2018; 7(12). PMC: 6306752. DOI: 10.3390/jcm7120507. View

12.

Garnero P, Thompson E, Woodworth T, Smolen J . Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy.... Arthritis Rheum. 2009; 62(1):33-43. DOI: 10.1002/art.25053. View

13.

Orstavik R, Haugeberg G, Mowinckel P, Hoiseth A, Uhlig T, Falch J . Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch Intern Med. 2004; 164(4):420-5. DOI: 10.1001/archinte.164.4.420. View

14.

Lee J, Sung Y, Choi C, Cho S, Bang S, Choe J . The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016; 17:98. PMC: 4765070. DOI: 10.1186/s12891-016-0952-8. View

15.

Malochet-Guinamand S, Lambert C, Gossec L, Soubrier M, Dougados M . Evaluation of the Implementation of Guidelines on the Treatment of Osteoporosis in Patients with Rheumatoid Arthritis. J Rheumatol. 2019; 47(1):6-14. DOI: 10.3899/jrheum.180889. View

16.

Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P . A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther. 2007; 9(3):R61. PMC: 2206336. DOI: 10.1186/ar2219. View

17.

Kume K, Amano K, Yamada S, Kanazawa T, Ohta H, Hatta K . The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology (Oxford). 2014; 53(5):900-3. DOI: 10.1093/rheumatology/ket468. View

18.

Hauser B, Riches P, Wilson J, Horne A, Ralston S . Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford). 2014; 53(10):1759-66. DOI: 10.1093/rheumatology/keu162. View

19.

Clynes M, Jameson K, Prieto-Alhambra D, Harvey N, Cooper C, Dennison E . Impact of Rheumatoid Arthritis and Its Management on Falls, Fracture and Bone Mineral Density in UK Biobank. Front Endocrinol (Lausanne). 2019; 10:817. PMC: 6888088. DOI: 10.3389/fendo.2019.00817. View

20.

Oelzner P, Schwabe A, Lehmann G, Eidner T, Franke S, Wolf G . Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int. 2008; 28(11):1143-50. DOI: 10.1007/s00296-008-0576-x. View